Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

14 results

  • Chapter 1 - Introduction

  • Edited by William J. Marks, Stanford University, California, Jill L. Ostrem, University of California, San Francisco
  • Book:
    Deep Brain Stimulation Management
    Published online:
    09 June 2022
    Print publication:
    30 June 2022, pp 1-3

  • Summary

    Since the publication of the first edition of this book more than two decades ago, the field of neuromodulation has undergone remarkable transformation. Deep brain stimulation (DBS) is now a firmly established treatment for movement disorders, and an increasing body of evidence supports DBS in the treatment of other neurological and psychiatric disorders. When DBS first arrived on the scene, the prospect of using a fully implantable neurostimulation system to deliver targeted, adjustable, nondestructive, and reversible brain modulation was paradigm shifting.

Deep Brain Stimulation Management
  • 3rd edition
  • Edited by William J. Marks, Jill L. Ostrem
  • Published online:
    09 June 2022
    Print publication:
    30 June 2022
  • Deep brain stimulation (DBS) is now a firmly established treatment for movement disorders, and an increasing body of evidence supports DBS in the treatment of other neurological and psychiatric disorders. This essential reference guide outlines a practical approach to the use of this paradigm-shifting therapy and covers key aspects of DBS practice. Chapters describe how to implement a DBS program and select appropriate patients, device programming to achieve optimal symptom control, and long-term management of patients. Thoroughly revised, this third edition includes additional chapters on managing patients with emerging applications of DBS. An entire chapter is dedicated to troubleshooting common problems with the therapy as many 'failures' are preventable and addressable. With contributions from experts in the field, this is a must-have reference guide for any clinician working with DBS patients.

  • Chapter 2 - Patient selection

  • Edited by William J. Marks, Jr, University of California, San Francisco
  • Book:
    Deep Brain Stimulation Management
    Published online:
    10 November 2010
    Print publication:
    28 October 2010, pp 4-19

  • Summary

    This chapter details factors that should be considered when evaluating each patient's candidacy for deep brain stimulation (DBS). A number of factors need to be assessed in a systematic matter to determine each patient's candidacy for treatment with DBS. Parkinson's disease (PD) patients referred for surgery are at greater risk for psychotic symptoms, as they usually have relatively advanced disease. When considering a patient with essential tremor (ET) for DBS, it is important to make sure the patient meets clinical criteria for the diagnosis of ET as a first step. Determining which dystonia patients are candidates for DBS can be challenging than making this determination for patients with PD or ET. An effective method for arriving at decisions regarding the candidacy of patients for treatment with DBS is to collect the required data for each patient and then convene a conference. These details are discussed by the interdisciplinary/multidisciplinary team.

  • Is There Cognitive Decline in Schizophrenia?: A Cross-sectional Study

  • Thomas M. Hyde, Safia Nawroz, Terry E. Goldberg, Llewellyn B. Bigelow, David Strong, Jill L. Ostrem, Daniel R. Weinberger, Joel E. Kleinman
  • Journal:
    The British Journal of Psychiatry / Volume 164 / Issue 4 / April 1994
    Published online by Cambridge University Press:
    02 January 2018, pp. 494-500
    Print publication:
    April 1994

  • The issue of progressive cognitive decline in patients with schizophrenia has been debated. We performed a cross-sectional study of patients with chronic schizophrenia, aged from 18 to 69 years, in order to address this issue. The patients included in this study passed a rigorous screen for any comorbid condition with an adverse impact on central nervous system function. We assessed intellectual deterioration with a battery of neuropsychological tests known to be sensitive to cognitive impairment in progressive dementia. No evidence of accelerated intellectual decline was found. No significant differences were found between the five age-derived cohorts (18–29, 30–39, 40–49, 50–59, and 60–69 years of age) on the Mini-Mental State Examination, Dementia Rating Scale, or other tests sensitive to dementia. While performance on the Boston Naming Test significantly declined with age, this was mainly due to age rather than duration of illness. However, it is important to note that mean performances on the majority of the tests were abnormal across all cohorts studied. These results suggest that intellectual function does not markedly decline during the adulthood of patients with schizophrenia. The course of schizophrenia is more consistent with a static encephalopathy than a dementing disorder.